Eli Lilly (LLY) Non-Current Deferred Tax Liability (2009 - 2022)

Eli Lilly (LLY) has reported Non-Current Deferred Tax Liability for 11 consecutive years, with $4.6 billion the latest figure, recorded in Q4 2022.

• Non-Current Deferred Tax Liability for Q4 2022 came in at $4.6 billion, up 164.12% year-over-year; the trailing twelve-month figure through Dec 2022 was $4.6 billion (up 164.12% YoY), and the FY2022 annual result was $4.6 billion, up 164.12% from the prior year.
• Non-Current Deferred Tax Liability was $4.6 billion for Q4 2022 at Eli Lilly, up from $171.9 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $5.1 billion in Q4 2020 and troughed at $171.9 million in Q3 2022.
• Average Non-Current Deferred Tax Liability over 5 years is $2.4 billion, with a median of $2.2 billion recorded in 2020.
• The widest YoY moves for Non-Current Deferred Tax Liability: up 164.12% in 2022, down 89.47% in 2022.
• Over 5 years, Non-Current Deferred Tax Liability stood at $3.0 billion in 2018, then soared by 51.61% to $4.6 billion in 2019, then grew by 10.13% to $5.1 billion in 2020, then tumbled by 65.81% to $1.7 billion in 2021, then jumped by 164.12% to $4.6 billion in 2022.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $4.6 billion in Q4 2022, $171.9 million in Q3 2022, and $862.5 million in Q2 2022.